People · Operator
Named in public records as an officer, director or promoter · active 2016–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Emulate, Inc. | — | Biotechnology | Series C | $182.3M | $1.5B | 2020 |
| Amphivena Therapeutics, Inc. | — | Biotechnology | Series B | $65.2M | $1.5B | 2018 |
| Pulse Therapeutics, Inc. | — | Biotechnology | Series A | $12.7M | $203.0M | 2016 |
| Euphrates Vascular, Inc. | — | Biotechnology | Series A | $9.7M | $322.2M | 2018 |
| Serotiny, Inc. | — | Biotechnology | Seed | $7.0M | $40.2M | 2018 |
| Partillion Bioscience Corp | — | Biotechnology | Series A | $4.9M | $52.9M | 2022 |
ERIC MOESSINGER at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside ERIC MOESSINGER on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Sean Morris | 2 | 7 |
| THOMAS HILLMAN | 2 | 3 |
| PAUL CONLEY | 1 | 17 |
| Luke Evnin | 1 | 12 |
| Robert Mitchell | 1 | 9 |
| Bevil J Hogg | 1 | 5 |
| Mark McDade | 1 | 5 |
| Phil Gutry | 1 | 4 |
| Frank Muhlenbeck | 1 | 4 |
| Aaron VanDevender | 1 | 3 |
| James Corbett | 1 | 3 |
| Shlomo Melmed | 1 | 3 |
| Michael Egholm | 1 | 3 |
| Sharon Kedar | 1 | 3 |
| Martin Madaus | 1 | 3 |
| Donald Ingber | 1 | 3 |
| Peter S. Finley | 1 | 2 |
| James C. Wachtman | 1 | 2 |
| TROY LONG | 1 | 2 |
| Gregory D. Williams | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.